

Gene Therapy

Part I: Technologies & Markets

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

December 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 27 books (5 as editor + 22 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (2008, 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer 2008; Chinese edition, Peking University Press 2011; 3rd ed Springer 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition. Chemical Industry Press 2016, 2nd ed Springer 2017) and "Handbook of Neuroprotection" (Springer 2011). Books that contain chapters on gene therapy include: Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and Applications of Biotechnology in Oncology (Springer 2014). He has also edited "Applied Neurogenomics" (Springer in 2015).

A B O U T T H I S R E P O R T

Prof. Jain wrote the first commercial report on Gene Therapy in 1995, which was published by PJB Publication, London. This was followed by reports on Gene Therapy Vectors and Cancer Gene Therapy (1996). A report on Gene Therapy of Neurological Disorders was published by Decision Resources in 1997. In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003. In 2004, when the copyright reverted to Prof. Jain, it became part II of the Gene Therapy report. This report supercedes and updates all the previous books as well as reports.

December 2017
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	21
1. Introduction	23
Definitions	23
Historical evolution of gene therapy	23
Relation of gene therapy to other biotechnologies.....	25
Molecular biological basics for gene therapy	26
Genome.....	26
DNA	26
RNA	27
<i>Alternative RNA splicing.....</i>	<i>28</i>
Genes.....	28
<i>Silent gene mutations.....</i>	<i>29</i>
Gene regulation	29
Gene expression	30
ENCODE	31
Chromosomes	31
Telomeres.....	32
Mitochondria	32
Proteins.....	33
2. Gene Therapy Technologies	35
Classification of gene therapy techniques.....	35
Ex vivo and in vivo gene therapy	36
Ex vivo gene therapy.....	36
In vivo gene therapy	37
Physical methods of gene transfer.....	37
Electroporation	37
Applications of electroporation	38
<i>Clinical applications of electroporation</i>	<i>39</i>
<i>Advantages of electroporation</i>	<i>40</i>
<i>Limitations of electroporation</i>	<i>40</i>
Hydrodynamic	40
Microinjection.....	41
Particle bombardment	41
Ultrasound-mediated transfection	43
Molecular vibration.....	44
Application of pulsed magnetic field and superparamagnetic nanoparticles	44
Gene transfection using laser irradiation	44
Photochemical transfection.....	45
Chemical methods of gene transfer	45
Gene repair and replacement.....	46
Gene repair by single-stranded oligonucleotides.....	46
History and current status of chimeraplasty	46
Genome editing.....	47
Gene editing by use of short synthetic oligonucleotides.....	47
Genome engineering by using TALENs.....	47
Gene editing by homing endonucleases	47
Targeted genome editing by artificial nucleases	48
Clinical applications of gene editing	48
Genome editing by using CRISPR system	49
<i>A method for generating genome-wide gRNA libraries for CRISPR</i>	<i>50</i>
<i>CRISPR for studying human embryogenesis</i>	<i>50</i>
<i>CRISPR for correction of a gene mutation in the human embryo</i>	<i>51</i>
<i>CRISPR system for creating animal models of human diseases.....</i>	<i>51</i>
<i>CRISPR/Cas9 technology for drug discovery</i>	<i>51</i>
<i>Expanding the range of Cas9s</i>	<i>52</i>
<i>Inducible CRISPR/Cas9 for multiple gene targeting</i>	<i>52</i>
<i>Photoactivatable CRISPR-Cas9.....</i>	<i>52</i>
<i>Protein delivery and genome editing.....</i>	<i>53</i>
<i>Potential clinical applications of CRISPR systems.....</i>	<i>53</i>
<i>PERV blockage by CRISPR to facilitate xenotransplantation</i>	<i>54</i>
<i>RNA editing with CRISPR.....</i>	<i>54</i>
<i>Clinical trial of CRISPR in human cancer.....</i>	<i>55</i>
<i>Complications and limitations of CRISPR/Cas9 technology.....</i>	<i>55</i>
<i>Companies developing CRISPR technology</i>	<i>56</i>
Base editing of the genome	56

Base editing by protein engineering.....	57
Adenine base editors for genomic DNA	57
mRNA gene therapy	57
Spliceosome mediated RNA trans-splicing	58
Vectors for gene therapy	58
Basic considerations	58
Use of genes as pharmaceuticals	58
The ideal vector for gene therapy.....	59
Viral vectors.....	59
<i>Adenovirus vectors</i>	60
<i>Adeno-associated virus vectors</i>	62
<i>Alphavirus vectors</i>	65
<i>Baculovirus vectors</i>	66
<i>Foamy virus vectors</i>	66
<i>Herpes simplex virus vectors</i>	66
<i>Lentiviral vectors</i>	69
<i>Multicistronic retroviral vectors</i>	69
<i>Retroviral vectors</i>	70
<i>Oncogenic potential of retroviral vectors</i>	71
<i>Quantification of viral vectors</i>	72
<i>Future of viral vectors</i>	72
<i>Companies using viral vectors</i>	73
Nonviral vectors for gene therapy	74
<i>Anionic lipid-DNA complexes</i>	75
<i>Cationic lipid-DNA complexes</i>	75
<i>Effects of shape of DNA molecules on delivery with nonviral vectors</i>	75
<i>Electrostatic modifications of surface to improve gene delivery</i>	76
<i>Liposomes for gene therapy</i>	76
<i>Liposome-nucleic acid complexes</i>	78
<i>Liposome-HVJ complex</i>	78
<i>Transposons DNA vectors</i>	78
<i>Polycation-DNA complexes (polyplexes)</i>	79
<i>Plasmid DNA vs minicircle DNA</i>	80
<i>Polymer vectors for gene therapy</i>	81
<i>Synthetic biology and DNA vectors</i>	81
<i>Synthetic peptide complexes</i>	82
<i>Future of nonviral vs viral vectors</i>	82
Nanobiotechnology for gene therapy	83
<i>Antisense nanoparticles</i>	83
<i>Dendrimers</i>	83
<i>Cochleates</i>	84
<i>Calcium phosphate nanoparticles as nonviral vectors</i>	84
<i>DNA nanoparticles as nonviral vectors</i>	84
<i>Gelatin nanoparticles for gene delivery</i>	84
<i>Lipid nanoparticles for nucleic acid delivery</i>	85
<i>Lipid nanoparticles for delivery of genome-editing proteins</i>	85
<i>Nanoparticles as nonviral vectors for gene therapy</i>	85
<i>Nanoparticles with virus-like function as gene therapy vectors</i>	86
<i>Nanobiologics for nucleic acid delivery</i>	86
<i>Nonionic polymeric micelles for oral gene delivery</i>	86
<i>Silica nanoparticles as a nonviral vector for gene delivery</i>	87
<i>Virus-like particles as nonviral vector</i>	87
Receptor-mediated endocytosis	87
Artificial viral vectors.....	88
Directed evolution of AAV to create efficient gene delivery vectors	89
Bacterial ghosts as DNA delivery systems	89
Bacteria plus nanoparticles for gene delivery into cells.....	90
Chromosome-based vectors for gene therapy.....	90
<i>Mammalian artificial chromosomes (MACs)</i>	91
<i>Human artificial chromosomes (HACs)</i>	91
<i>ΦC31 integrase system</i>	92
Companies using nonviral vectors	92
Concluding remarks about vectors	93
Cell-mediated gene therapy	94
Fibroblasts	94
Skeletal muscle cells	95
Vascular smooth muscle cells	96
Keratinocytes	96
Hepatocytes	96
Lymphocytes.....	96
<i>Regulating protein delivery by genetically encoded lymphocytes</i>	97

Implantation of microencapsulated genetically modified cells	97
Stem cell gene therapy	98
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	98
<i>Improving delivery of genes to stem cells</i>	98
<i>Lentiviral vectors for gene transfer to marrow stem cells</i>	99
<i>Use of mesenchymal stem cells for gene therapy</i>	99
<i>Microporation for transfection of MSCs</i>	99
<i>In utero gene therapy using stem cells</i>	99
<i>Gene delivery to stem cells by artificial chromosome expression</i>	100
<i>Linker based sperm-mediated gene transfer technology</i>	100
<i>Combination of gene therapy with therapeutic cloning</i>	100
<i>Expansion of transduced HSCs in vivo</i>	100
<i>The future of hematopoietic stem cell gene therapy</i>	101
Role of genetically modified bacteria in gene therapy	101
Routes of administration for gene therapy	102
Direct injection of naked DNA	102
Intramuscular injection	103
Intravenous DNA injection	103
Intraarterial delivery	103
Companies with gene delivery devices/technologies	103
Targeted gene therapy.....	104
Targeted integration.....	105
Bacteriophage integrase system for site-specific gene delivery	105
Controlled-release delivery of DNA	106
Controlled gene therapy	106
Controlled delivery of genetic material	106
Controlled induction of gene expression	107
Drug-inducible systems for control of gene expression.....	107
Timed activation of gene therapy by a circuit based on signaling network	108
Small molecules for post-transcriptional regulation of gene expression	108
Engineered zinc finger DNA binding proteins for gene correction	108
Light Activated Gene Therapy.....	109
Spatial control of gene expression via local hyperthermia.....	109
Companies with regulated /targeted gene therapy	109
Gene marking	110
Germline gene therapy	111
Potential applications of human germline genome modification	111
Pros and cons of human germline genome modification	111
Role of gene transfer in antibody therapy.....	113
Genetically engineered vaccines	113
DNA vaccines	113
<i>DNA inoculation technology</i>	114
<i>Methods for enhancing the potency of DNA vaccines</i>	114
<i>Advantages of DNA vaccines</i>	115
Vaccine vectors	115
Challenges and limitations of genetically engineered vaccines.....	116
RNA vaccines.....	116
<i>Nonviral delivery of self-amplifying RNA vaccine</i>	116
Vaccines based on reverse genetics.....	117
Technologies for gene suppression.....	117
Antisense oligonucleotides	117
Transcription factor decoys	118
Aptamers.....	118
Ribozymes	119
Peptide nucleic acid.....	119
<i>Intracellular delivery of PNAs</i>	119
Locked nucleic acid	120
<i>Zorro-LNA</i>	120
Gene silencing	120
Post-transcriptional gene silencing	121
Definitions and terminology of RNAi	121
RNAi mechanisms	121
Inhibition of gene expression by antigenic RNA	122
RNAi gene therapy	123
microRNA gene therapy	123
Viral vectors for RNAi and miRNA gene therapy	123
Application of molecular diagnostic methods in gene therapy	124
Use of PCR to study biodistribution of gene therapy vector	125
PCR for verification of the transcription of DNA	125
In situ PCR for direct quantification of gene transfer into cells	125
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	126

Confirmation of viral vector integration	126
Monitoring of gene expression	126
<i>Monitoring of gene expression by green fluorescent protein</i>	126
<i>Monitoring in vivo gene expression by molecular imaging</i>	127
<i>Advantages of gene therapy compared with protein therapy</i>	127
Formulation, transport and storage of materials for gene therapy	127

3. Clinical Applications of Gene Therapy	129
Introduction	129
Aging research.....	129
Bone and joint disorders.....	129
Bone fractures.....	129
Gene therapy for intervertebral disc degeneration.....	130
Spinal fusion	131
Osteogenesis imperfecta	131
Rheumatoid arthritis.....	132
<i>Local or systemic treatment</i>	132
<i>In vivo or ex vivo gene therapy of RA</i>	132
<i>Clinical trials of gene therapy for rheumatoid arthritis</i>	133
Gene therapy for osteoarthritis.....	134
Sports injuries.....	136
<i>Repair of articular cartilage defects</i>	136
Regeneration and replacement of bone by gene therapy	137
Bacterial infections	137
Antisense approach to bacterial infections	138
Dentistry.....	138
Tissue engineering in dental implant defects	138
Endocrine and metabolic disorders	139
Introduction	139
Gene therapy of obesity.....	139
<i>AAV vector-mediated delivery of GDNF for obesity</i>	139
<i>Oligopeptide for targeted nonviral gene delivery to adipocytes</i>	139
<i>Viral vector-mediated leptin gene therapy</i>	140
Diabetes mellitus	140
Methods of gene therapy of diabetes mellitus	141
<i>Viral vector-mediated gene transfer in diabetes</i>	142
<i>Gene delivery with ultrasonic microbubble destruction technology</i>	142
<i>Genetically engineered cells for diabetes mellitus</i>	143
<i>Genetically altered liver cells</i>	143
<i>Genetically modified stem cells</i>	143
<i>Genetically engineered dendritic cells</i>	144
<i>Glucokinase and insulin co-expression</i>	144
<i>Leptin gene therapy</i>	144
<i>Concluding remarks about cell and gene therapy of diabetes</i>	144
Gene therapy of growth-hormone deficiency	145
Gastrointestinal disorders.....	146
Introduction	146
Methods of gene transfer to the gastrointestinal tract.....	146
<i>Direct delivery of genes</i>	146
<i>Naked plasmid DNA into the submucosa</i>	147
<i>Viral vectors</i>	147
<i>Receptor-mediated endocytosis</i>	147
Indications for gastrointestinal gene therapy	147
<i>Gene therapy for inflammatory disorders of the bowel</i>	148
Gene transfer to the salivary glands.....	149
<i>Potential clinical applications of salivary gene therapy</i>	149
Hematology	150
Hemophilias	150
<i>Gene therapy of hemophilia</i>	150
<i>Hemophilia A</i>	151
<i>Hemophilia B</i>	152
<i>Concluding remarks about gene therapy of hemophilias</i>	153
Hemoglobinopathies	154
<i>Gene therapy for β-thalassemia</i>	154
<i>Gene therapy for sickle cell disease</i>	156
<i>Gene therapy and RNAi for SCD based on stem cells</i>	156
<i>Gene editing in sickle cell disease</i>	157
<i>Gene editing using ZFN as treatment for both SCD and β-thalassemia</i>	157
<i>Gene editing using CRISPR-Cas9 for both SCD and β-thalassemia</i>	157
<i>Gene therapy of Fanconi's anemia</i>	157
Acquired hematopoietic disorders.....	158

<i>Chronic acquired anemias</i>	158
<i>Neutropenia</i>	159
<i>Thrombocytopenia</i>	159
Concluding remarks about gene therapy of hemoglobinopathies	160
Companies involved in gene therapy of hematological disorders	160
In utero/fetal gene therapy	161
Fetal gene transfer techniques	161
Animal models of fetal gene therapy	162
Potential applications of fetal gene therapy	162
<i>Fetal gene therapy for cystic fibrosis</i>	163
<i>Fetal intestinal gene therapy</i>	163
<i>Gene therapy for fetal growth restriction</i>	163
Hearing disorders	164
Potential of gene therapy	164
Vectors for gene therapy of hearing disorders	165
Auditory hair cell replacement and hearing improvement by gene therapy	165
Kidney diseases	166
End-stage renal disease	166
Methods of gene delivery to the kidney	166
<i>Gene transfer into kidney by adenoviral vectors</i>	167
<i>Non-viral gene transfer to the kidneys</i>	167
<i>Gene transfer into the glomerulus by HVJ-liposome</i>	167
<i>Bone marrow stem cells for renal disease</i>	167
<i>Mesangial cell therapy</i>	168
<i>Liposome-mediated gene transfer into the tubules</i>	168
<i>Gene transfer to tubules with cationic polymer polyethylenimine</i>	168
Gene therapy in animal experimental models of renal disease	169
Genetic manipulations of the embryonic kidney	169
Antisense intervention in glomerulonephritis	169
Gene therapy for renal fibrosis	170
Use of genetically engineered cells for uremia due to renal failure	170
Concluding remarks	171
Liver disorders	171
Techniques of gene delivery to liver	172
<i>Direct injection of DNA into liver</i>	172
<i>Local gene delivery by isolated organ perfusion</i>	172
<i>Liposome-mediated direct gene transfer</i>	172
<i>Retroviral vector for gene transfer to liver</i>	172
<i>Adenoviral vectors for gene transfer to liver</i>	173
<i>Receptor-mediated approach</i>	173
Cell therapy for liver disorders	173
<i>Transplantation of genetically modified hepatocytes</i>	174
<i>Genetically modified hematopoietic stem cells</i>	174
<i>Gene therapy by ex vivo transduced liver progenitor cells</i>	174
Gene therapy of genetic diseases affecting the liver	175
<i>Crigler-Najjar syndrome</i>	175
<i>Hereditary tyrosinemia type I (HT1)</i>	175
<i>Hereditary tyrosinemia type 3</i>	176
Gene therapy of acquired diseases affecting the liver	176
<i>Cirrhosis of liver</i>	176
Ophthalmic disorders	176
Introduction to gene therapy of ophthalmic disorders	176
Methods of gene therapy for ophthalmic disorders	177
<i>Delivery of gene therapy by intravitreal injection</i>	178
<i>DNA nanoparticles for nonviral gene transfer to the eye</i>	179
<i>Optogenetic gene therapy for blindness due to retinal degeneration</i>	179
Age-related macular degeneration	180
Inherited disorders of optic nerve affecting vision	181
<i>Leber hereditary optic neuropathy</i>	181
Inherited retinal degenerations	182
<i>Choroideremia</i>	183
<i>Leber congenital amaurosis</i>	184
<i>Retinitis pigmentosa</i>	186
<i>Stargardt disease</i>	187
Other inherited disorders affecting vision	187
<i>Color blindness</i>	187
<i>Usher syndrome</i>	188
<i>X-linked retinoschisis</i>	189
Diabetic retinopathy	190
Future prospects of gene therapy of inherited retinal degenerations	190
<i>Combining cell and gene therapies for retinal disorders</i>	190

Prevention of complications associated with eye surgery	191
<i>Prevention of proliferative retinopathy by gene therapy</i>	191
<i>Posterior capsule opacification after cataract surgery</i>	191
Autoimmune uveitis	191
Retinal ischemic injury.....	191
Corneal disorders.....	192
Glaucoma	192
Corneal scarring	193
Companies developing gene therapy for eye disorders.....	193
Organ transplantation.....	193
Introduction	193
DNA vaccines for transplantation	194
Gene therapy for prolonging allograft survival	194
<i>Genetically modified Tregs expressing CAR for preventing GVHD</i>	194
Gene therapy in lung transplantation.....	195
Role of gene therapy in liver transplantation	195
Gene therapy in kidney transplantation.....	195
Veto cells and transplant tolerance.....	196
Pulmonary disorders.....	196
Techniques of gene delivery to the lungs	197
<i>Adenoviral vectors</i>	197
<i>Nonviral vectors</i>	198
<i>Aerosolization as an aid to gene transfer to lungs.</i>	198
Cystic fibrosis.....	199
<i>Genetics and clinical features</i>	199
<i>Gene therapy for CF</i>	199
<i>CFTR gene transfer in CF</i>	199
<i>Concluding remarks about gene therapy of CF</i>	201
Miscellaneous pulmonary disorders	201
<i>Gene therapy for pulmonary arterial hypertension</i>	201
<i>Gene therapy for bleomycin-induced pulmonary fibrosis</i>	202
<i>Gene therapy of emphysema due to α1-antitrypsin deficiency</i>	202
<i>Gene therapy for asthma</i>	203
<i>Gene therapy for adult respiratory distress syndrome</i>	203
<i>Gene therapy for lung injury</i>	203
<i>Gene therapy for bronchopulmonary dysplasia</i>	204
Concluding remarks about gene therapy of lungs.....	204
Companies involved in pulmonary gene therapy	205
Skin and soft tissue disorders.....	206
Gene transfer to the skin	206
<i>Electroporation for transdermal delivery of plasmid DNA</i>	206
<i>Electroporation for transdermal delivery of DNA vaccines</i>	207
<i>Liposomes for transdermal gene delivery</i>	207
<i>Ultrasound and topical gene therapy</i>	207
Gene therapy in skin disorders	207
<i>Gene therapy of hair loss</i>	208
<i>Gene therapy for epidermolysis bullosa</i>	208
<i>Gene therapy for xeroderma pigmentosa</i>	210
<i>Gene therapy for lamellar ichthyosis</i>	210
Gene transfer techniques for wound healing	210
Urogenital disorders	211
Gene therapy for urinary tract dysfunction	211
Gene therapy for erectile dysfunction	211
<i>NOS gene transfer for erectile dysfunction</i>	211
<i>Clinical trial of hMaxi-K Gene transfer in erectile dysfunction</i>	212
<i>Gene therapy for erectile dysfunction due to nerve injury</i>	212
<i>Concluding remarks on gene therapy for erectile dysfunction</i>	212
Veterinary gene therapy	212
Gene therapy for mucopolysaccharidosis VII in dogs	213
Gene therapy to increase disease resistance.....	213
Gene therapy for infections	213
Gene therapy for chronic anemia	214
Gene therapy for endocrine disorders	214
Gene therapy for arthritis.....	214
Cancer gene therapy	215
<i>Brain tumors in cats and dogs</i>	215
<i>Breast cancer in dogs</i>	215
<i>Canine hemangiosarcoma</i>	216
<i>Canine melanoma</i>	216
<i>Canine soft tissue sarcoma</i>	217
Melanoma in horses	217

4. Gene Therapy of Genetic Disorders	219
Introduction	219
Primary immunodeficiency disorders	220
Severe combined immune deficiency	221
Chronic granulomatous disease	224
Wiskott-Aldrich syndrome	224
Purine nucleoside phosphorylase deficiency	225
Major histocompatibility class II deficiency	225
Future prospects of gene therapy of inherited immunodeficiencies	226
Metabolic disorders	226
Alpha1-antitrypsin deficiency.....	227
<i>AAV mediated gene therapy for a1-antitrypsin deficiency</i>	227
<i>iPSCs for targeted gene correction of a1-antitrypsin deficiency</i>	228
Adrenoleukodystrophy	229
Canavan disease.....	230
Lesch-Nyhan syndrome	231
Lipoprotein lipase deficiency.....	231
<i>Alipogene tiparvovec</i>	231
Ornithine transcarbamylase deficiency.....	232
<i>Gene therapy for OTCD</i>	232
<i>AAV-mediated gene editing for OTCD using CRISPR-Cas9</i>	233
Phenylketonuria.....	233
Porphyrias	234
Tetrahydrobiopterin deficiency.....	235
Lysosomal storage disorders	235
Batten disease.....	236
Fabry's disease.....	237
Farber's disease.....	237
Gaucher disease	237
<i>Animals models of Gaucher's disease</i>	238
<i>Gene therapy of Gaucher's disease</i>	238
Hunter syndrome.....	239
Krabbe's disease	239
Metachromatic leukodystrophy	240
Mucopolysaccharidosis type 1 (Hurler syndrome).....	241
Niemann-Pick type A disease.....	242
Pompe disease	242
Sanfilippo A syndrome.....	242
Sly syndrome	243
Tay-Sachs disease	243
Future prospects of gene therapy of lysosomal storage disorders	244
Trinucleotide repeat disorders	244
Muscular dystrophies	244
Duchenne muscular dystrophy (DMD).....	245
<i>Animal models for gene therapy of DMD</i>	245
<i>Antisense approaches to DMD</i>	246
<i>Exon-skipping for DMD</i>	246
<i>Galgt2 gene therapy</i>	247
<i>Liposome-mediated gene transfer</i>	247
<i>Microdystrophin gene therapy</i>	248
<i>Myoblast-based gene transfer in DMD</i>	248
<i>Plasmid-mediated gene therapy</i>	248
<i>Purinoreceptor P2RX7 ablation</i>	249
<i>Post-transcriptional modulation of gene expression in DMD</i>	249
<i>Repair/Editing of dystrophin gene</i>	249
<i>Routes of administration of gene therapy in DMD</i>	252
<i>Types of dystrophin constructs</i>	253
<i>Viral vectors for DMD</i>	253
<i>Conclusions and future of gene therapy of DMD</i>	254
Limb-girdle muscular dystrophy.....	255
Myotonic dystrophy	255
Spinal muscular atrophy	256
<i>Gene therapy for SMA</i>	256
<i>Antisense therapy of SMA</i>	257
<i>Nusinersen</i>	257
<i>Nusinersen vs scAAV9 gene therapy for SMA</i>	258
X-linked myotubular myopathy (XLMTM).....	258
Hereditary neuropathies	258
Charcot-Marie-Tooth disease	258
Hereditary axonal neuropathies of the peripheral nerves.....	259
Gene therapy of mitochondrial disorders	259

Techniques for mitochondrial replacement therapy.....	260
Status of mitochondrial replacement and transfer therapies	260
Companies involved in gene therapy of genetic disorders	261
5. Gene Therapy of Cancer.....	263
Strategies for cancer gene therapy.....	263
Direct gene delivery to the tumor	264
Injection into tumor	264
<i>Direct injection of adenoviral vectors.....</i>	<i>264</i>
<i>Direct injection of a plasmid DNA-liposome complex.....</i>	<i>265</i>
<i>A polymer approach to local gene therapy for cancer.....</i>	<i>265</i>
Electroporation for cancer gene therapy.....	265
Control of gene expression in tumor by local heat	266
Radiation-guided gene therapy of cancer	266
Radioprotective gene therapy	266
Nanoparticles to facilitate combination of hyperthermia and gene therapy.....	267
Cell-based cancer gene therapy	267
Adoptive cell therapy.....	267
Cytokine gene therapy.....	268
Genetic modification of human hematopoietic stem cells.....	271
Immunogene therapy	271
Cancer vaccines	272
Genetically modified cancer cell vaccines	272
<i>GVAX cancer vaccines</i>	<i>272</i>
<i>Genetically modified dendritic cells.....</i>	<i>273</i>
Nucleic acid-based cancer vaccines	273
<i>DNA cancer vaccines</i>	<i>273</i>
<i>RNA vaccines.....</i>	<i>273</i>
Viral vector-based cancer vaccines	274
<i>Intradermal delivery of cancer vaccines by Ad vectors</i>	<i>274</i>
Future of cancer vaccines.....	275
Companies involved in nucleic acid-based cancer vaccines	275
Monoclonal antibody gene transfer for cancer	276
Transfer and expression of intracellular adhesion-1 molecules	276
Other gene therapy techniques for immunotherapy of cancer	276
Chemokines	277
CRISPR for immunogene therapy	277
Engineered viruses as anticancer immunotherapy vectors	278
Fas (Apo-1).....	278
Major Histocompatibility Complex (MHC) Class I	278
IGF (Insulin-Like Growth Factor).....	279
Inhibition of immunosuppressive function in cancer	279
Delivery of toxic genes to tumor cells for eradication	279
Gene-directed enzyme prodrug therapy	279
Combination of gene therapy with radiotherapy	280
Correction of genetic defects in cancer cells	280
Targeted gene therapy for cancer.....	281
Antiangiogenic therapy for cancer	281
Bacteria as novel anticancer gene vectors	282
Cancer-specific gene expression	282
Cancer-specific transcription.....	282
Delivery of retroviral particles hitchhiking on T cells	283
Electrogene and electrochemotherapy	283
Epidermal growth factor-mediated DNA delivery	283
Gene expression in hypoxic tumor cells	284
Genetically modified T cells for targeting tumors.....	284
<i>Chimeric antigen receptor T cells</i>	<i>285</i>
<i>CAR-T cells targeting both CD19 and CD22</i>	<i>287</i>
Genetically engineered stem cells for targeting tumors	287
Hematopoietic stem cells for targeted cancer gene therapy	288
Immunolipoplex for delivery of p53 gene	288
Nanomagnets for targeted cell-based cancer gene therapy.....	289
Nanoparticles for targeted site-specific delivery of anticancer genes	289
Targeted cancer therapy using a dendrimer-based synthetic vector.....	290
Tumor-targeted gene therapy by receptor-mediated endocytosis	290
Virus-mediated oncolysis	290
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i>	<i>290</i>
<i>Monitoring of viral-mediated oncolysis by PET.....</i>	<i>291</i>
<i>Oncolytic adenoviruses</i>	<i>291</i>
<i>Oncolytic HSV.....</i>	<i>292</i>
<i>Oncolytic measles viruses</i>	<i>293</i>

<i>Oncolytic vaccinia virus</i>	293
<i>Oncolytic vesicular stomatitis virus</i>	294
<i>Targeted cancer treatments based on oncolytic viruses</i>	294
<i>Concluding remarks on oncolytic gene therapy</i>	294
<i>Companies developing oncolytic viruses</i>	295
Apoptotic approach to improve cancer gene therapy	296
Tumor suppressor gene therapy	296
P53 gene therapy.....	296
BRIT1 gene therapy.....	297
Nitric oxide-based cancer gene therapy	297
Anticancer effect of nitric oxide synthase.....	297
Gene therapy for radiosensitization of cancer.....	297
Gene therapy of cancer of selected organs	297
Gene therapy for bladder cancer.....	298
Gene therapy for glioblastoma multiforme.....	298
<i>Adenoviral vectors for treatment of brain tumors</i>	299
<i>Antiangiogenic gene therapy</i>	300
<i>Autophagy induced by conditionally replicating adenoviruses</i>	300
<i>Baculovirus vector for diphtheria toxin gene therapy</i>	301
<i>Cerepro® (sitimagene ceradenovec)</i>	301
<i>Gene therapy targeting hepatocyte growth factor</i>	301
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i>	302
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	302
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	302
<i>Olig2 targeting to hinder growth of treatment-resistant glioblastomas</i>	303
<i>RNAi gene therapy of brain cancer</i>	303
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	303
<i>Viral oncolysis of glioblastoma multiforme</i>	304
Gene therapy for breast cancer.....	305
<i>Gene vaccine for breast cancer</i>	306
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	306
Gene Therapy for ovarian cancer.....	307
Gene therapy for malignant melanoma.....	307
<i>Immunogene therapy</i>	308
<i>Nonviral immunogene therapy for malignant melanoma</i>	309
<i>Oncogene targeted therapy</i>	309
<i>Targeted gene therapy for malignant melanoma</i>	309
Gene therapy of lung cancer.....	310
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene</i>	310
<i>Aerosol gene delivery for lung cancer</i>	310
Gene therapy for cancer of prostate.....	311
<i>Experimental studies</i>	311
<i>Nanoparticle-based gene therapy for prostate cancer</i>	311
<i>Tumor suppressor gene therapy in prostate cancer</i>	311
<i>Vaccines for prostate cancer</i>	312
<i>Viral oncolysis for prostate cancer</i>	312
<i>Clinical trials of gene therapy for prostate cancer</i>	312
Gene therapy of head and neck cancer.....	313
<i>Adenoviral vector based P53 gene therapy</i>	313
<i>Gene therapy as adjunct to 5-FU for nasopharyngeal carcinoma</i>	313
Gene therapy of pancreatic tumors.....	314
<i>Pancreatic neuroendocrine tumors</i>	314
<i>Pancreatic ductal adenocarcinoma</i>	314
<i>Correction of altered genes</i>	315
<i>Targeted gene therapy</i>	315
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i>	315
<i>Targeted Expression of BikDD gene</i>	316
<i>Viral oncolysis in pancreatic cancer</i>	316
<i>Concluding remarks on gene therapy of pancreatic cancer</i>	316
Gene therapy of renal cancer.....	316
<i>Viral oncolytic therapy for renal cancer</i>	316
Gene therapy of hematological malignancies.....	317
<i>Genetically engineered T lymphocytes</i>	317
Cancer gene therapy companies	317
6. Gene Therapy of Neurological Disorders	321
Indications	321
Gene transfer techniques for the nervous system	322
Methods of gene transfer to the nervous system.....	322
Ideal vector for gene therapy of neurological disorders.....	322
Promoters of gene transfer.....	322

Lentivirus-mediated gene transfer to the CNS	323
AAV vector mediated gene therapy for neurogenetic disorders.....	323
Gene transfer to the CNS using recombinant SV40-derived vectors	324
Routes of delivery of genes to the CNS	324
<i>Direct injection into CNS</i>	324
<i>Introduction of the genes into cerebral circulation</i>	325
<i>Introduction of genes into cerebrospinal fluid</i>	325
<i>Intravenous administration of vectors</i>	326
Delivery of gene therapy to the peripheral nervous system	326
Cell-mediated gene therapy of neurological disorders	326
<i>Neuronal cells</i>	326
<i>Neural stem cells and progenitor cells</i>	326
<i>Astrocytes</i>	327
<i>Cerebral endothelial cells</i>	327
<i>Implantation of genetically modified encapsulated cells into the brain</i>	327
Gene transfer for neuromodulation.....	327
Gene therapy of neurodegenerative disorders	328
Gene therapy for Parkinson disease.....	328
Rationale	329
<i>Techniques of gene therapy for PD</i>	329
<i>Augmenting CNS glucocerebrosidase activity</i>	332
<i>Delivery of neurotrophic factors by gene therapy</i>	333
<i>Delivery of parkin gene</i>	333
<i>Introduction of functional genes into the brain of patients with PD</i>	333
<i>Nanoparticle-based gene therapy for PD</i>	334
<i>Mitochondrial gene therapy for PD</i>	334
<i>RNAi approach to PD</i>	334
<i>Prospects of gene therapy for PD</i>	335
<i>Concluding remarks about gene therapy of PD</i>	336
<i>Companies developing gene therapy for PD</i>	336
Gene therapy for Alzheimer disease	336
<i>Rationale</i>	336
<i>NGF gene therapy for AD</i>	337
<i>FGF2 gene transfer in AD</i>	338
<i>Nepriylsin gene therapy</i>	338
<i>Targeting plasminogen activator inhibitor type-1 gene</i>	339
<i>Viral gene transfer of APP_s for rescuing synaptic failure in AD</i>	339
<i>Gene vaccination</i>	339
<i>Combination of gene therapy with other treatments for AD</i>	340
Gene therapy of Huntington disease.....	340
<i>Encapsulated genetically engineered cellular implants</i>	340
<i>Viral vector mediated administration of neurotrophic factors</i>	340
<i>RNAi gene therapy</i>	341
Gene therapy of amyotrophic lateral sclerosis.....	341
<i>Rationale</i>	341
<i>Technique of gene therapy of ALS</i>	341
<i>Other approaches to gene therapy of ALS</i>	342
Gene therapy of cerebrovascular diseases	342
Preclinical research in gene therapy for cerebrovascular disease	343
Animal models of stroke relevant to gene therapy.....	343
<i>Transgenic mice as models for stroke</i>	343
<i>Animal models for gene therapy of arteriovenous malformations</i>	344
Gene transfer to cerebral blood vessels	344
Gene therapy for vasospasm following subarachnoid hemorrhage	345
<i>NOS gene therapy for cerebral vasospasm</i>	346
Gene therapy for stroke.....	346
<i>Gene therapy for stroke using neurotrophic factors</i>	347
<i>Gene therapy of strokes with a genetic component</i>	348
<i>Gene therapy for intracranial aneurysms</i>	348
<i>RNAi-based gene silencing for neuroprotection in cerebral ischemia</i>	348
Concluding remarks about gene therapy for stroke.....	348
Gene therapy of injuries to the nervous system.....	349
Traumatic brain injury	349
Spinal cord injury.....	349
Peripheral nerve injuries	350
Gene therapy of epilepsy	350
Gene therapy for control of seizures	351
Gene therapy for neuroprotection in epilepsy	352
Gene therapy for genetic forms of epilepsy	352
Gene therapy for multiple sclerosis	353
Gene therapy for impairment of special senses	353

Gene therapy for hearing loss.....	353
Gene therapy for olfactory impairment	354
Gene therapy for relief of pain	355
Rationale of gene therapy for pain	355
Vectors for gene therapy of pain	355
Methods of gene delivery for pain	355
<i>Endogenous analgesic production for cranial neuralgias</i>	<i>356</i>
<i>Gene delivery by intrathecal route</i>	<i>356</i>
<i>Gene transfer for delivery of analgesics to the spinal nerve roots</i>	<i>357</i>
<i>Gene therapy of peripheral neuropathic pain</i>	<i>358</i>
<i>Gene transfer by injections into the brain substance.....</i>	<i>359</i>
Targets for gene therapy of pain	359
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	<i>359</i>
<i>Gene therapy for producing enkephalin to block pain signals</i>	<i>359</i>
<i>Targeting nuclear factor-κB</i>	<i>360</i>
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	<i>360</i>
Potential applications of gene therapy for management of pain.....	361
Concluding remarks on gene therapy for pain	361
Gene therapy for psychiatric disorders	362
Gene therapy for depression	362
Gene therapy for enhancing cognition after stress.....	363
Gene therapy against fear disorders.....	363
Companies involved in gene therapy of neurological disorders.....	363

7. Gene Therapy of Cardiovascular Disorders 365

Introduction	365
Techniques of gene transfer to the cardiovascular system	365
Direct plasmid injection into the myocardium	366
Catheter-based systems for vector delivery	366
Ultrasound microbubbles for cardiovascular gene delivery	367
Vectors for cardiovascular gene therapy	367
<i>AAV vectors for therapeutic delivery to the heart</i>	<i>367</i>
<i>Adenoviral vectors for cardiovascular diseases.....</i>	<i>368</i>
<i>Molecular cardiac surgery with recirculating delivery of AAV vectors</i>	<i>368</i>
<i>Plasmid DNA-based delivery in cardiovascular disorders.....</i>	<i>368</i>
Gene therapy for counteracting hypoxia in myocardial ischemia.....	368
Therapeutic angiogenesis vs vascular growth factor therapy.....	369
Gene painting for delivery of targeted gene therapy to the heart	369
Gene delivery to vascular endothelium	370
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	370
Vascular stents for gene delivery	371
Gene therapy for genetic cardiovascular disorders	371
Catecholaminergic polymorphic ventricular tachycardia.....	371
Genetic disorders predisposing to atherosclerosis.....	372
Familial hypercholesterolemia.....	373
Apolipoprotein E deficiency.....	374
Hypertension.....	375
Genetic factors for myocardial infarction	375
Acquired cardiovascular diseases	376
Coronary artery disease with angina pectoris.....	376
<i>Ad5FGF-4.....</i>	<i>376</i>
Gene therapy for improving long-term CABG patency rates.....	377
Ischemic heart disease with myocardial infarction	377
<i>Gene therapy and angiogenesis in ischemic heart disease</i>	<i>378</i>
<i>Induction of angiogenesis in myocardium by HEXIM1 re-expression</i>	<i>378</i>
<i>Myocardial repair with IGF-1 therapy.....</i>	<i>379</i>
<i>Metalloproteinase-2 inhibitor gene therapy.....</i>	<i>379</i>
<i>miRNA gene therapy for ischemic heart disease</i>	<i>380</i>
Congestive heart failure.....	380
<i>Rationale of gene therapy in CHF</i>	<i>380</i>
<i>AAV-mediated gene transfer for CHF</i>	<i>381</i>
<i>AngioCell gene therapy for CHF</i>	<i>381</i>
<i>β-ARKct gene therapy.....</i>	<i>382</i>
<i>Elevating cardiac dATP by gene therapy to improve cardiac function.....</i>	<i>382</i>
<i>Elevating cardiac adenylyl cyclase type 6 to improve cardiac function.....</i>	<i>383</i>
<i>Intracoronary adenovirus-mediated gene therapy for CHF.....</i>	<i>384</i>
<i>nNOS gene transfer in CHF.....</i>	<i>384</i>
Cardiomyopathies	384
Cardiac conduction disturbances	385
<i>Gene transfer approaches for biological pacemakers.....</i>	<i>385</i>
<i>Genetically engineered biological pacemakers.....</i>	<i>386</i>

Gene therapy and heart transplantation.....	386
Hyperlipidemia and hypercholesterolemia	387
<i>Antisense approach to hypertriglyceridemia</i>	387
<i>Cholesterol reduction by genetic engineering of PCSK9 gene</i>	387
<i>Inactivating variants in ANGPTL4 for lowering circulating triglycerides</i>	387
Peripheral arterial disease	388
Incidence and clinical features	388
Current management	388
Gene therapy for peripheral arterial disease	388
<i>Angiogenesis by gene therapy</i>	388
<i>HIF-1α gene therapy for peripheral arterial disease</i>	389
<i>HGF gene therapy for peripheral arterial disease</i>	389
Prevention of restenosis after angioplasty	390
<i>Antisense approaches</i>	390
<i>Gene therapy to prevent restenosis after angioplasty</i>	391
<i>hTIMP-1 gene therapy to prevent intimal hyperplasia</i>	392
<i>miRNA-based gene therapy for restenosis</i>	392
<i>NOS gene therapy for restenosis</i>	393
<i>Techniques of gene therapy for restenosis</i>	393
Maintaining vascular patency after surgery	394
Companies involved in gene therapy of cardiovascular diseases	394
Future of gene therapy of cardiovascular disorders.....	395
8. Gene therapy of viral infections.....	397
Introduction	397
Acquired Immunodeficiency Syndrome (AIDS).....	397
Current management of AIDS.....	397
Gene therapy strategies in HIV/AIDS.....	398
<i>HIV/AIDS vaccines</i>	398
<i>Insertion of protective genes into target cells</i>	399
Cell/gene therapies for HIV/AIDS	400
<i>Transplantation of genetically modified T cells</i>	400
<i>Transplantation of genetically modified hematopoietic cells</i>	401
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells</i>	402
Inhibition of HIV-1 replication by lentiviral vectors	402
<i>VRX496-T</i>	402
Intracellular immunization.....	403
Engineered cellular proteins such as soluble CD4s.....	403
Intracellular antibodies	403
Anti-rev single chain antibody fragment.....	404
Use of genes to chemosensitize HIV-1 infected cells.....	404
Autocrine interferon (INF)- β production by somatic cell gene therapy	404
Antisense approaches to AIDS	404
<i>RNA decoys</i>	404
<i>Antisense oligodeoxynucleotides</i>	405
<i>RNA decoys</i>	405
<i>Ribozymes</i>	405
RNAi applications in HIV/AIDS	406
<i>siRNA-directed inhibition of HIV-1 infection</i>	406
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	407
<i>Bispecific siRNA constructs</i>	407
<i>Targeting CXCR4 with siRNAs</i>	407
<i>Targeting CCR5 with siRNAs</i>	408
Companies involved in developing gene therapy for HIV/AIDS	408
Conclusions regarding gene therapy of HIV/AIDS.....	409
Genetic vaccines for other viral infections	409
Cytomegalic virus infections	409
Viral hepatitis	410
<i>Vaccine for hepatitis B</i>	410
<i>Vaccine for hepatitis C</i>	411
<i>Gene therapy for hepatitis C</i>	411
Vaccine for herpes simplex virus.....	411
DNA vaccine against rabies	412
DNA vaccine for Ebola	412
Vaccines for avian influenza	413
<i>Future prospects of DNA vaccines for avian influenza</i>	413
<i>Human trial of a DNA vaccine for avian influenza</i>	414
Companies developing genetic vaccines for infections other than AIDS	414
9. Research, Development and Future of Gene Therapy.....	417
Basic research in gene therapy.....	417

R & D in gene therapy	417
Animal models of human diseases for gene therapy research	418
<i>Lentiviral transgenesis</i>	418
Financing research and development	418
Role of the NIH in gene therapy research	418
National Gene Vector Laboratories	418
Funding of gene therapy research in Europe	419
<i>Gene therapy funding in Horizon 2020 of European Commission</i>	419
Financing by the industry	420
Clinical trials in gene therapy	420
Clinical trials worldwide	420
<i>Clinical trials in cancer gene therapy</i>	421
<i>Trials of gene therapy for neurological disorders</i>	421
<i>Clinical trials for genetic disorders</i>	421
<i>Clinical trials in cardiovascular gene therapy</i>	421
<i>Clinical trials for infectious diseases</i>	421
<i>Gene therapy for other disorders</i>	421
Clinical trials in the US.....	422
Vectors used in gene therapy clinical trials	422
<i>Vector analytics for clinical trials using rAAV vectors</i>	423
Future prospects for the gene therapy	423
How to improve gene therapy.....	424
International Gene Therapy Consortium.....	424
Future opportunities and challenges for gene therapy	426
Promising areas of application of gene therapy	426
<i>Neurological disorders</i>	427
<i>Gene therapy of cardiovascular disorders</i>	427
<i>Cancer gene therapy</i>	428
Personalized gene therapy	429
10. Regulatory, Safety, Ethical Patent Issues of Gene Therapy	431
Regulation of gene therapy in the United States	431
US Federal guidelines for research involving recombinant DNA molecules	431
Regulation of gene therapy in US	431
Implantation of genetically manipulated cells.....	431
<i>Modification of oocytes for use in IVF</i>	432
Clinical trials in gene therapy	432
Cell and gene therapy INDs placed on hold by the FDA	432
Regulation of gene therapy in Europe	433
European Union	433
Regulation of gene therapy in Germany	434
<i>Preclinical research</i>	434
<i>Clinical Trials</i>	435
Marketing authorization	436
Regulation of gene therapy in the United Kingdom	436
Regulation of gene therapy in France.....	437
Regulation of gene therapy in Italy	437
Regulation of gene therapy in the Netherlands.....	438
Gene therapy regulation in Switzerland.....	439
Regulation of gene therapy in Australia	439
Regulation of gene therapy in Japan	440
Regulation of gene therapy in China	440
Safety issues of gene transfer	441
Adverse effects of retroviral vectors	441
<i>Insertional mutagenesis</i>	441
Adverse effects of HSV vectors	442
<i>Neurotoxicity of HSV vectors</i>	442
<i>Hepatotoxicity of HSV-tk/ganciclovir approach</i>	442
Adverse effects of adenoviral vectors.....	443
<i>Inflammatory effects of adenoviruses in lungs</i>	443
<i>Inflammatory effects involving the liver</i>	443
<i>Induction of immune response by adenoviral vectors</i>	444
<i>Impairment of adrenocortical steroidogenesis</i>	444
<i>Adverse effects of AAV vectors</i>	444
Toxicity associated with cationic lipid-mediated gene transfer	445
Toxicity of lipopolysaccharides	445
Potential side effects of RNAi gene therapy.....	445
Role of molecular diagnostics in safety of gene therapy	446
Quality control of vectors	446
<i>Testing for retroviruses</i>	446
<i>Adenoviral vectors</i>	446

<i>Replication competent viruses</i>	447
Genetic characteristics of viral vectors	447
Concluding remarks about safety of viral vectors	447
Ethical aspects of gene therapy	448
The lay consumer's view of somatic gene therapy ethics	448
Ethical aspects of clinical trials.....	449
Regulatory and ethical issues for in utero gene therapy	449
Ethical aspects of germline gene therapy	449
Ethical aspects of mitochondrial replacement therapy	450
Ethical aspects of gene editing.....	450
<i>Ethical aspects of clinical trials of germline editing</i>	451
<i>Gene editing in the UK</i>	451
<i>Gene editing in the US</i>	452
<i>UNESCO's view on gene editing in humans</i>	453
Germline gene therapy for genetic enhancement	454
Athletic enhancement by genetic engineering	454
<i>Gene doping in sports</i>	454
<i>Gene transfer methods used for enhancing physical performance</i>	454
<i>Adverse effect of genetic engineering</i>	456
<i>Problems in detecting genetic manipulations in athletes</i>	457
<i>Ethical dilemma</i>	457
Gene therapy patents	457
CRISP/Cas9 patents	458
11. Markets for Gene Therapy	461
Introduction	461
Gene therapy markets in various regions of the world	461
Gene therapy markets according to therapeutic areas	462
Cancer gene therapy market	462
Markets for gene therapy of genetic disorders	462
Markets for DNA vaccines	463
DNA vaccines markets according to technologies	463
DNA vaccines markets according to therapeutic indications	464
DNA vaccines markets according to geographical areas	464
Competing treatments	465
Antisense.....	465
RNAi.....	465
Cell therapy	465
Strategies for developing gene therapy markets	466
<i>Collaboration with pharmaceutical companies</i>	466
<i>Collaboration with companies developing cell-based therapies</i>	466
<i>Collaboration with academic gene therapy centers</i>	466
<i>Developing safer and cost-effective gene medicines</i>	466
<i>Intellectual property and commercialization of gene therapy</i>	466
<i>Overcoming obstructions to the development of gene therapy</i>	467
Unmet needs in gene therapy	467
Promises and challenges for the development of gene therapy	468
Development of gene therapy market in China	468
Challenges of developing gene therapy in the USA	469
Challenges of developing gene therapy in the European Union.....	469
12. References	471

Tables

Table 1-1: Landmarks in development of gene therapy.....	23
Table 2-1: Classification of methods of gene therapy.....	35
Table 2-2: A comparison of various physical methods of gene transfer	37
Table 2-3: Experimental applications of gene transfer by electroporation	38
Table 2-4: Companies developing CRISPR technology	56
Table 2-5: An overview of characteristics of commonly used viral vectors	60
Table 2-6: Companies using viral vectors.....	73
Table 2-7: Companies using nonviral vectors	92
Table 2-8: Target organs for nonviral gene therapy methods.	94
Table 2-9: Potential routes for administration of DNA	102
Table 2-10: Companies with gene delivery devices/ technologies.....	103
Table 2-11: Strategies for targeted gene therapy	105
Table 2-12: Animal experimental studies of in vivo gene delivery with polymer systems.....	106

Table 2-13: Approaches to controlling gene expression in gene therapy	107
Table 2-14: Companies with regulated/targeted gene therapy and special techniques	109
Table 2-15: Potential applications of human germline genome modification	111
Table 2-16: Applications of molecular diagnostics in gene therapy	125
Table 2-17: Advantages of gene therapy compared with protein therapy	127
Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis	133
Table 3-2: Gene therapy strategies for osteoarthritis.....	134
Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus.....	141
Table 3-4: Indications for gastrointestinal gene therapy	148
Table 3-5: Hematological disorders that can be potentially treated by gene therapy.....	150
Table 3-6: Companies involved in gene therapy of hematological disorders.....	161
Table 3-7: Techniques of gene transfer to the kidneys.....	166
Table 3-8: Gene therapy in animal experimental models of renal disease.....	169
Table 3-9: Applications of gene therapy in ophthalmological disorders.....	177
Table 3-10: Companies developing gene therapy for eye disorders	193
Table 3-11: Strategies for gene delivery to the lungs	197
Table 3-12: Companies developing gene therapy for pulmonary disorders	206
Table 4-1: Genetic disorders that are being investigated for gene therapy	219
Table 4-2: X-linked immunodeficiency disorders	221
Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy	226
Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy	245
Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders	262
Table 5-1: Strategies for cancer gene therapy	263
Table 5-2: Cell-based gene therapy for cancer	267
Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines.....	275
Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy.....	279
Table 5-5: Mutation compensation strategies used clinically	280
Table 5-6: Companies developing oncolytic viruses	295
Table 5-7: Strategies for gene therapy of malignant brain tumors.....	298
Table 5-8: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	305
Table 5-9: Clinical trials of gene therapy in ovarian cancer.....	307
Table 5-10: Gene therapy for malignant melanoma.....	308
Table 5-11: Clinical trials of gene therapy for prostate cancer	313
Table 5-12: Companies involved in cancer gene therapy.....	317
Table 6-1: Example of potential indications for gene therapy of neurologic disorder	321
Table 6-2: Methods of gene transfer as applied to neurologic disorders	322
Table 6-3: Gene therapy techniques applicable to Parkinson disease	328
Table 6-4: Companies developing gene therapy for Parkinson's disease.....	336
Table 6-5: Gene transfer in animal models of carotid artery restenosis.....	344
Table 6-6: Gene therapy strategies for vasospasm.....	345
Table 6-7: Neuroprotective gene therapy in animal stroke models	346
Table 6-8: Experimental gene therapy approaches for relief of pain	356
Table 6-9: Companies involved in gene therapy of neurological disorders	363
Table 7-1: Cardiovascular disorders that are potential indications for gene therapy.....	365
Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system.....	366
Table 7-3: Companies involved in gene therapy of cardiovascular diseases	394
Table 8-1: Strategies for gene therapy of AIDS	398
Table 8-2: Companies involved in developing gene therapy for HIV/AIDS	408
Table 8-3: Companies developing genetic vaccines for infections other than AIDS	414
Table 9-1: Geographical distribution of gene therapy clinical trials	420
Table 9-2: Opportunities and challenges for gene therapy and resources needed	426
Table 9-3: Potential applications of gene therapy in disorders of the nervous system	427
Table 10-1: Genes that may be used for performance enhancement	455
Table 11-1: Gene therapy market according to regions/countries – 2016 to 2026	461
Table 11-2: Gene therapy markets according to therapeutic areas – 2016 to 2026.....	462
Table 11-3: Cancer gene therapy market according to type of cancer - 2016 to 2026.....	462
Table 11-4: Gene therapy market for selected genetic disorders - 2016 to 2026.....	463
Table 11-5: DNA vaccines markets according to technologies - 2016 to 2026.....	463
Table 11-6: DNA vaccines markets according to therapeutic indications - 2016 to 2026.....	464
Table 11-7: DNA vaccines markets according to geographical areas - 2016 to 2026.....	464

Figures

Figure 1-1: Relation of gene therapy to other biotechnologies	25
Figure 1-2: Relationship of DNA, RNA and protein in the cell	29
Figure 2-1: Ex vivo and in vivo techniques of gene therapy.....	36
Figure 2-2: Structure of the Helios gene gun.....	42
Figure 2-3: A scheme of CRISPR/Cas9 gene editing	49
Figure 2-4: Categories of rAAV-based gene therapy strategies	63
Figure 2-5: Bacteria plus nanoparticles for drug delivery into cells	90

Figure 2-6: Schematic of suppression of gene expression by RNAi	122
Figure 3-1: Retina and routes of administration of gene therapy for retinal disorders	183
Figure 4-1: Targeted gene correction of α 1-antitrypsin deficiency by iPSCs	229
Figure 4-2: Application of CRISPR-Cas9 in a mouse model of DMD.....	250
Figure 4-3: Techniques for mitochondrial nuclear transfer.....	260
Figure 5-1: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	285
Figure 5-2: Gene therapy approaches for pancreatic cancer	314
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels	329
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage.....	349
Figure 9-1: Product development cycle in gene therapy.....	417
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US.....	422
Figure 9-3: Proportions of various vectors used in gene therapy trials	422
Figure 10-1: Evaluation system of gene therapy clinical studies in Japan	440
Figure 11-1: Unmet needs in gene therapy	468